Lupus Research Alliance Awards $450K to Two Lupus Therapy Projects
Event summary
- Lupus Research Alliance awarded $450,000 each to two research projects under its 2026 Translational Bridge Awards program.
- Recipients include Nunzio Bottini (Cedars-Sinai) for an antibody therapy targeting cutaneous lupus erythematosus (CLE).
- Jim Oates (Medical University of South Carolina) is investigating L-sepiapterin for lupus nephritis treatment.
- Both projects build on discoveries previously funded by the 2021 Lupus Innovation Awards.
- Awards aim to accelerate development of therapies for skin and kidney manifestations of lupus.
The big picture
The Lupus Research Alliance's 2026 Translational Bridge Awards highlight the persistent gap between lupus research discoveries and patient-ready therapies. With $900,000 allocated to two promising projects, the organization is addressing critical unmet needs in skin and kidney manifestations of lupus. This strategic focus on translational research reflects broader industry efforts to accelerate development of targeted therapies for autoimmune diseases, particularly where current treatments fall short.
What we're watching
- Clinical Translation
- Whether these projects can successfully transition from preclinical research to human trials within the two-year funding period.
- Therapeutic Impact
- The potential for these therapies to address significant unmet needs in lupus skin and kidney manifestations.
- Funding Continuity
- How the Lupus Research Alliance will sustain support for these projects beyond the initial $450,000 grants.